Dynavax Technologies Corp DVAX
We take great care to ensure that the data presented and summarized in this overview for DYNAVAX TECHNOLOGIES CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DVAX
View all-
Black Rock Inc. New York, NY21.9MShares$221 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT17.8MShares$179 Million6.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$84.9 Million0.0% of portfolio
-
State Street Corp Boston, MA6.4MShares$64.4 Million0.0% of portfolio
-
Chicago Capital, LLC4.31MShares$43.4 Million1.06% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.64MShares$36.7 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.89MShares$29.1 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA2.69MShares$27.1 Million0.0% of portfolio
-
Blair William & CO Chicago, IL2.28MShares$23 Million0.06% of portfolio
-
Kynam Capital Management, LP Princeton, NJ2.15MShares$21.6 Million2.54% of portfolio
Latest Institutional Activity in DVAX
Top Purchases
Top Sells
About DVAX
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Insider Transactions at DVAX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 22
2025
|
Scott Dunseth Myers Director |
BUY
Open market or private purchase
|
Direct |
3,800
+9.79%
|
$38,000
$10.82 P/Share
|
|
Aug 22
2025
|
Deep Track Biotechnology Master Fund, Ltd. |
SELL
Open market or private sale
|
Direct |
970,143
-5.81%
|
$9,701,430
$10.59 P/Share
|
|
Aug 21
2025
|
Deep Track Biotechnology Master Fund, Ltd. |
SELL
Open market or private sale
|
Direct |
1,094,994
-6.15%
|
$12,044,934
$11.03 P/Share
|
|
Jun 11
2025
|
Lauren P Silvernail Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,439
+12.5%
|
-
|
|
Jun 11
2025
|
Scott Dunseth Myers Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,758
+15.58%
|
-
|
|
Jun 11
2025
|
Daniel L Kisner Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,758
+19.8%
|
-
|
|
Jun 11
2025
|
Emilio Emini Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,439
+12.5%
|
-
|
|
Jun 11
2025
|
Peter R. Paradiso Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,758
+18.83%
|
-
|
|
Jun 11
2025
|
Francis Cano Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,758
+11.89%
|
-
|
|
Jun 11
2025
|
Brent Mac Gregor Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,758
+20.87%
|
-
|
|
Jun 11
2025
|
Elaine D Sun Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,758
+16.16%
|
-
|
|
Mar 24
2025
|
David F Novack President & COO |
SELL
Open market or private sale
|
Direct |
10,000
-55.32%
|
$140,000
$14.0 P/Share
|
|
Mar 24
2025
|
David F Novack President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+35.62%
|
$60,000
$6.8 P/Share
|
|
Mar 18
2025
|
David F Novack President & COO |
SELL
Open market or private sale
|
Direct |
14,020
-63.44%
|
$182,260
$13.58 P/Share
|
|
Mar 07
2025
|
David F Novack President & COO |
SELL
Open market or private sale
|
Direct |
32,764
-59.72%
|
$458,696
$14.39 P/Share
|
|
Feb 18
2025
|
John L Slebir SVP General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
5,358
-12.84%
|
$64,296
$12.93 P/Share
|
|
Feb 18
2025
|
John L Slebir SVP General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
16,667
+28.54%
|
-
|
|
Feb 18
2025
|
Robert Janssen SVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,041
-4.96%
|
$48,492
$12.93 P/Share
|
|
Feb 18
2025
|
Robert Janssen SVP and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,904
+12.74%
|
-
|
|
Feb 18
2025
|
Kelly Mac Donald SVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,975
-14.55%
|
$59,700
$12.93 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 314K shares |
|---|---|
| Grant, award, or other acquisition | 37.4K shares |
| Open market or private purchase | 3.8K shares |
| Payment of exercise price or tax liability | 144K shares |
|---|---|
| Open market or private sale | 2.12M shares |